KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Work In Process (2016)

AbbVie (ABBV) has disclosed Work In Process for 5 consecutive years, with $1.1 billion as the latest value for Q2 2016.

  • On a quarterly basis, Work In Process rose 4.81% to $1.1 billion in Q2 2016 year-over-year; TTM through Jun 2016 was $1.1 billion, a 4.81% increase, with the full-year FY2015 number at $1.1 billion, up 71.86% from a year prior.
  • Work In Process was $1.1 billion for Q2 2016 at AbbVie, down from $1.1 billion in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $1.1 billion in Q1 2016 to a low of $262.0 million in Q1 2013.
  • A 5-year average of $672.0 million and a median of $568.0 million in 2015 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: surged 122.85% in 2015, then grew 4.81% in 2016.
  • AbbVie's Work In Process stood at $286.0 million in 2012, then surged by 41.26% to $404.0 million in 2013, then surged by 55.69% to $629.0 million in 2014, then surged by 71.86% to $1.1 billion in 2015, then dropped by 1.2% to $1.1 billion in 2016.
  • Per Business Quant, the three most recent readings for ABBV's Work In Process are $1.1 billion (Q2 2016), $1.1 billion (Q1 2016), and $1.1 billion (Q4 2015).